Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

June 24, 2017
Paul A. Hamlin, MD

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

Cerdulatinib is an oral dual Syk/JAK inhibitor that is currently being evaluated in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and indolent lymphomas such as follicular lymphoma and peripheral T-cell lymphoma.

This is an open-label, phase II cohort-driven expansion study, preliminary results of which are being presented at the 2017 European Hematology Association Congress.

x